B
BioAtla, Inc. (BCAB)
NCM – Real vaqt narxi. Valyuta: USD
4.54
+0.02 (0.44%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.50
-0.06 (-1.32%)
Bozor oldidan: May 13, 2026, 7:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
4.54
+0.02 (0.44%)
Yopilishda: May 12, 2026, 4:00 PM EDT
4.50
-0.06 (-1.32%)
Bozor oldidan: May 13, 2026, 7:00 AM EDT
BioAtla, Inc., klinik tadqiqot bosqichidagi biofarmatsevtika kompaniyasi, qattiq o'sma saratonini davolash uchun maxsus va tanlab antitelalarga asoslangan terapiyalarni ishlab chiqadi. Uning yetakchi klinik tadqiqot bosqichidagi mahsulot nomzodlari orasida undiferensial pleomorfik sarkoma va mayda hujayrali o'pka saratonini (NSCLC) davolash uchun shartli faol biologik (CAB) antitelalari-dorivor kon'yugati (ADC) bo'lgan mecbota mab vedotin (BA3011); va melanooma va orofarengeal yassi hujayrali karsinomani davolash uchun CAB ADC bo'lgan ozuriftab mab vedotin (BA3021) mavjud. Kompaniya, shuningdek, melanooma, buyrak hujayrali karsinoma, kolorektal saraton va NSCLCni davolash uchun CAB sitotoksik T-limfotsit-assotsiatsiyalashgan antigen 4 antitelasi bo'lgan Evalstotug (BA3071); adenokarsinomalarni davolash uchun bispesifik nomzod bo'lgan BA3182; o'smalarni davolash uchun CAB-Nectin-4-ADC bo'lgan BA3361; turli qattiq o'smalarda ifodalangan B7-H3 oqsiliga qaratilgan ikkilamchi CAB T-hujayrali ingichka bo'lgan BA3142; va CAB-Nectin 4 x CAB-CD3 uchun preklinik nomzodni ishlab chiqmoqda. Kompaniya 2007 yilda tashkil etilgan va shtab-kvartirasi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Dr. Jay M. Short Ph.D. | Co-Founder, CEO & Chairman |
| Lisa M. Pelton | Accounting Manager |
| Ms. Monica Sullivan | Senior Vice President of Intellectual Property & Contracts |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-29 | 10-K/A | bcab-20251231.htm |
| 2026-04-02 | 8-K | bcab-20260402.htm |
| 2026-03-31 | 8-K | bcab-20260331.htm |
| 2026-03-31 | 10-K | bcab-20251231.htm |
| 2026-03-23 | 8-K | bcab-20260317.htm |
| 2026-03-02 | DEFA14A | n5620_x3-defa14a.htm |
| 2026-03-02 | 8-K | n5620_8k.htm |
| 2026-02-11 | DEFM14A | n5620_x2-defm14a.htm |
| 2026-02-09 | 8-K | d317360d8k.htm |
| 2026-02-06 | 8-K | bcab-20260206.htm |
| Ms. Sheri Lydick | Chief Commercial Officer |
| Ms. Susie Melody | Senior Vice President of Human Resources |